TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02219984

Intervention type: DRUG
Intervention: Anticoagulants
Study: NCT00377325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 4 mg/Kg/day; daily; liquid form; 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 4 mg/Kg/day; daily; liquid form; 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclosporine
Description: 4 mg/Kg/day; daily; liquid form; 6 months
Study: NCT04639674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: If no other medicines are taken usually, take AST-120 one hour after each meal with a frequency of three doses a day and one dose every administration. The drug will be taken for four weeks.
Study: NCT01367509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX)
Study: NCT01648270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: Session 1 Intravenous buprenorphine: 0.2 mg over 1 hr Session 2 Sublingual buprenorphine: 2 mg Session 3 Intravenous buprenorphine 0.2 mg over 1 hr beginning 1 hr after starting cyclosporine Session 4 Sublingual buprenorphine: 2 mg after cyclosporine.
Study: NCT02381522

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Pre-conditioning

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham RIPC
Study: NCT03752216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Two different doses of Niraparib can be administrated:~For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.~For patient who had at baseline (T0) a body weight \< 77 kg or a platelet count \<150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.~Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria.
Study: NCT01676337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message appointment reminder
Description: Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
Study: NCT00411593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 g/kg by vein every 3 weeks on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Phase I Starting dose: 1.6 mg/m2 by vein on days 1, 8 of each 3 week cycle.~Phase II: MTD from Phase I.
Study: NCT00225433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: follitropin beta
Description: Follitropin beta

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ganirelix acetate
Description: Ganirelix acetate
Study: NCT03703466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.
Study: NCT02992990

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bladder tumor biopsy
Description: Bladder tumor biopsy performed at the time of the preoperative office flexible cystoscopic evaluation.
Study: NCT04398537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5mm retraction of clip deployment apparatus.
Description: Advancing the clip to the biopsy site and retracting 5 mm and then deploying. This is one method of standard of care and involves depositing the clip after retraction of the deployment apparatus 5 mm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No retraction of clip deployment apparatus.
Description: This is one method of standard of care and the clip will be deployed at the biopsy site.
Study: NCT03538951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% VDA-1102
Description: 200 mg twice-daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% VDA-1102
Description: 200 mg once-daily for 12 weeks
Study: NCT02420730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-232411
Description: AGN-232411 topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-232411
Description: AGN-232411 topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-232411
Description: AGN-232411 topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-232411
Description: AGN-232411 topical ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-232411
Description: AGN-232411 topical ophthalmic solution
Study: NCT02697851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon 30®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon 30®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evotaz®
Study: NCT00673491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pathways
Description: Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period. Defining characteristics of clinical pathways includes: an explicit statement of the goals and key elements of care based on evidence, best practice, and patient expectations; the facilitation of the communication, coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives; the documentation, monitoring, and evaluation of variances and outcomes; and the identification of the appropriate resources.
Study: NCT02748109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation + audio biofeedback
Description: Vestibular rehabilitation paired with audio biofeedback for balance control 2 times per week with a physical therapist for 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation
Description: Standard vestibular rehabilitation 2 times per week with a physical therapist for 6 weeks.
Study: NCT03690479

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Florida Probe Straight Tip Probe
Description: Twenty (20) consecutive adult patients with a diagnosis of periodontal disease (varying degrees, from slight to severe) will be selected to undergo full-mouth periodontal probing. . One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip.
Study: NCT02420730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-232411
Description: AGN-232411 topical ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-232411 Vehicle
Description: Vehicle for AGN-232411 topical ophthalmic solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-232411 Vehicle
Description: Vehicle for AGN-232411 topical ophthalmic solution.
Study: NCT00935402

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep
Description: Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep
Description: Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.
Study: NCT02697851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evotaz®
Study: NCT00942591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta 1b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study: NCT01579084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Formulation A
Description: AGN-199201 Formulation A applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Formulation A
Description: AGN-199201 Formulation A applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: AGN-199201 Formulation A
Description: AGN-199201 Formulation A applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Formulation A
Description: AGN-199201 Formulation A applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Formulation B
Description: AGN-199201 Formulation B applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Formulation B
Description: AGN-199201 Formulation B applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Formulation B
Description: AGN-199201 Formulation B applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: AGN-199201 Formulation B
Description: AGN-199201 Formulation B applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Formulation C
Description: AGN-199201 Formulation C applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Formulation C
Description: AGN-199201 Formulation C applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Formulation C
Description: AGN-199201 Formulation C applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: AGN-199201 Formulation C
Description: AGN-199201 Formulation C applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: AGN-199201 Vehicle
Description: AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: AGN-199201 Vehicle
Description: AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
Study: NCT03920228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-022
Description: PTX-022 QTORIN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-022
Description: PTX-022 QTORIN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-022
Description: PTX-022 QTORIN

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo topical
Study: NCT06723314

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Subperiosteal Tunnel Access vista
Description: CAF procedures were performed (Split-Full-Split flap), following the anesthetic agent, the sulcular incision was performed by a full thickness vertical incision till the muccogingival junction• Split thickness releasing incision was made at the flap base with full thickness flap reflection till the muccogingival junction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular Subperiosteal Tunnel Access vista
Description: CAF procedures were performed (Split-Full-Split flap), following the anesthetic agent, the sulcular incision was performed by a full thickness vertical incision till the muccogingival junction• Split thickness releasing incision was made at the flap base with full thickness flap reflection till the muccogingival junction.
Study: NCT00385580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression
Study: NCT03690479

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ball Tip Probe
Description: Twenty (20) consecutive patients meeting the inclusion criteria will be selected to undergo full-mouth periodontal probing. The opposing jaw will be probed using the new trial tip. At a second visit, prior to treatment, the mouth will be probed once again, alternating the jaws from the first visit.
Study: NCT00385580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression
Study: NCT02945384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Creating Connections: Strong Families, Strong Brains
Description: Dual-generation intervention
Study: NCT04468256

Intervention type: OTHER
Intervention: COVID-19 experience surveys
Description: Serial online surveys recording experiences of the COVID-19 pandemic.

Intervention type: OTHER
Intervention: COVID-19 experience surveys
Description: Serial online surveys recording experiences of the COVID-19 pandemic.
Study: NCT01766674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kyphosis spinal strengthening exercises
Description: Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
Study: NCT03387033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relaxation response and virtual reality (VR) session
Description: A 10-minute relaxation response (mindfulness and deep breathing) followed by 10-minute immersive VR session.
Study: NCT01928446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
Study: NCT01472198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Description: Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match simtuzumab
Description: Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
Study: NCT00969475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumenis fractional carbon dioxide laser
Description: intra-operative laser resurfacing at time of wound closure
Study: NCT03087955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acoziborole (SCYX-7158)
Study: NCT00003508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with advanced mesothelioma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.hourly interEach infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT04575168

Intervention type: DIAGNOSTIC_TEST
Intervention: Spartan COVID-19 Test
Description: A nasopharyngeal sample analyzed on the Spartan COVID-19 System.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spartan COVID-19 Test
Description: A nasopharyngeal sample analyzed on the Spartan COVID-19 System.
Study: NCT01928446

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets will be administered for the duration of follow-up (1 year).
Study: NCT01834885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 via inhaler twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol
Description: fluticasone/slameterol via inhaler twice a day
Study: NCT04046042

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: Virtual reality exercise performed during the first two hours of the hemodialysis session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise during the last two hours of the hemodialysis session
Description: Virtual reality exercise performed during the last two hours of the hemodialysis session
Study: NCT04295395

Intervention type: DEVICE
Intervention: NONIN SenSmart model X-100 near- infrared spectrometer
Description: for to measure cerebral (cSO2) and renal (rSO2 ) regional tissue oxygen saturation on the day after echocardiography was done. The sensors were placed on the right/left forehead and the right/left lateral posterior flank

Intervention type: DEVICE
Intervention: NONIN SenSmart model X-100 near- infrared spectrometer
Description: for to measure cerebral (cSO2) and renal (rSO2 ) regional tissue oxygen saturation on the day after echocardiography was done. The sensors were placed on the right/left forehead and the right/left lateral posterior flank
Study: NCT03625401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-35 60mg group
Description: AD-35 60mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo: 3 placebo of AD-35 30mg tablets
Study: NCT04295395

Intervention type: DEVICE
Intervention: NONIN SenSmart model X-100 near- infrared spectrometer
Description: for to measure cerebral (cSO2) and renal (rSO2 ) regional tissue oxygen saturation on the day after echocardiography was done. The sensors were placed on the right/left forehead and the right/left lateral posterior flank
Study: NCT04366479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multistage Fitness Test
Description: Participants only joined in one group will be given intervention for 5 weeks in the form of running 1600 meters duration of 20-30 minutes 3 times a week. It is important for the participants as well as for us to know which training methods are given. this information will be documented in our file, but we will not see these files until after the research is complete. this is the best way we have for testing without being influenced by what we think or expect might happen.
Study: NCT02300025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: single oral 10-mg dose of cobimetinib
Study: NCT04274452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod
Description: Intravenous infusion of efgartigimod

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo
Study: NCT02300025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: single oral 10-mg dose of cobimetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: single oral 10-mg dose of cobimetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: single oral 10-mg dose of cobimetinib
Study: NCT01126515

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Imaging of the brain without gadolinium will be performed with a 3 Tesla magnetic resonance (MR) System (Intera Achieva 3T; Philips Medical Systems). The protocol will include anatomical sequences, a diffusion tensor imaging sequence with fiber tracking, and auditory, visual, and motor functional magnetic resonance imaging (MRI).

Intervention type: PROCEDURE
Intervention: Computed Tomography Angiography
Description: Computed tomography angiography (CTA) with intravenous (IV) contrast will be performed on a 320 head computed tomography (CT) scanner, assessing brain perfusion.
Study: NCT03687125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine
Description: Participants received tinostamustine IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine
Description: Participants received tinostamustine IV injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant (ASCT)
Description: Undergo autologous stem cell transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant (ASCT)
Description: Undergo autologous stem cell transplant
Study: NCT01982487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 inhibitor INCB024360
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 inhibitor INCB024360
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies